Drugs / IM21 CAR-T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05478343 | May 2021 → May 2023 | plasma cell myeloma | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04537442 | Sep 2020 → Dec 2022 | plasma cell myeloma | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03711864 | Feb 2019 → Oct 2021 | plasma cell myeloma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IM21 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04537442 ↗ |
| Action | Deplete | “BCMA CAR-T could effectively eradicate CNS-involved MM” PMID 35651792 ↗ May 2022 |
| Modality | Cell therapy | “CAR-T cell infusion” NCT03711864 ↗ |